Analysts have recently shared their insights on three prominent healthcare companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR), and Ionis Pharmaceuticals (IONS).
Michael Yee from UBS maintained a Buy rating on Johnson & Johnson, setting a price target of $320.00. The stock closed last Thursday at $256.48. Yee, a 3-star analyst with a 1.1% average return and a 44.7% success rate, covers stocks like Vertex Pharmaceuticals and Bristol-Myers Squibb. The consensus among analysts is a Strong Buy for JNJ, with an average price target of $289.71, suggesting a 13.1% upside. Scotiabank also maintained a Buy rating with a $305.00 price target.
Jason Gerberry from Bank of America Securities reiterated a Hold rating on United Therapeutics, with a price target of $559.00. The stock closed at $532.78. Gerberry, a 5-star analyst with an 18.5% average return and a 58.7% success rate, covers stocks like Harmony Biosciences and Amylyx Pharmaceuticals. The general consensus for UTHR is a Moderate Buy, with an average price target of $643.00, indicating an 18.0% upside. Morgan Stanley also maintained a Hold rating with a $566.00 price target.
Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ionis Pharmaceuticals, setting a price target of $100.00. The stock closed at $43.30. Kapoor, a 4-star analyst with a 5.9% average return and a 36.0% success rate, covers stocks like Kyverna Therapeutics and BioMarin Pharmaceutical. The consensus for IONS is a Strong Buy, with an average price target of $84.00, representing a 92.0% upside. Needham also maintained a Buy rating with an $86.00 price target.